Navigation Links
Life Technologies Announces Third Quarter 2011 Results
Date:10/25/2011

CARLSBAD, Calif., Oct. 25, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for its third quarter ending September 30, 2011. Non-GAAP revenue for the third quarter was $929 million, an increase of 7 percent over the $869 million reported for the third quarter of 2010. Excluding the impact of currency, revenue growth for the quarter was 4 percent compared to the same period of the prior year.

(Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

"We are pleased with our third quarter results.  We have seen an improvement in our Greater China business and continue to gain traction with our Ion Torrent products," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies.  "Although academic government funding pressures are expected to continue in the U.S. and Europe, we are positioning our products and cost structure to succeed in this new environment."

Analysis of Third Quarter 2011 Results

  • Third quarter non-GAAP 2011 revenue increased 7 percent over the prior year.  Revenue growth without the impact from currency was 4 percent.
  • Non-GAAP gross margin in the third quarter was 66.1 percent, approximately 70 basis points lower than the same period of the prior year due to the negative impact from higher instrument sales and lower royalty revenue, partially offset by the positive impact from productivity and price.
  • Non-GAAP operating margin was 29.4 percent in the third quarter, approximately 40 basis points higher than the same period of the prior year.  Operating margin improvement was primarily due to the company's continued focus on operational efficiencies.
  • Third quarter non-GAAP tax rate was 27.1 percent.
  • Diluted weighted shares outstanding were 186.8 million in the third quarter, a decrease of 3.3 million shares over the prior year.  The decrease was a result of the continuation of the company's share repurchase program, partially offset by dilution from employee equity programs.  The company has repurchased $100 million or 2.6 million shares in the last 90 days, 1.9 million of which were repurchased within the third quarter.
  • Cash flow from operating activities for the third quarter was $174 million.  Third quarter capital expenditures were $32 million, resulting in free cash flow of $142 million. The company ended the quarter with $636 million in cash and short-term investments.
  • The following analysis of diluted earnings per share identifies specific items that affect the comparability of results between periods. Reconciliations between the company's GAAP and non-GAAP results for the periods reported are presented in the attached tables and on the company's Investor Relations page at http://ir.lifetechnologies.com.

  • Three Months Ending Sept 3020112010%GAAP earnings per share

    $0.52

    $0.56

    (7%)Non-cash interest expense (FSP APB14-1)

    0.02

    0.03Business integration and other charges

    0.08

    0.06Amortization of acquisition related expenses

    0.32

    0.22Non-GAAP earnings per share$0.94$0.878%Business Highlights:

  • Cell Systems division non-GAAP revenue was $244 million in the third quarter, an increase of 10 percent over the same period last year.  Excluding the impact from currency, revenue grew 6 percent year over year.  This growth was a result of solid growth across the portfolio, as well as low double digit growth in BioProduction and improvements in Asia.
  • Molecular Biology Systems division non-GAAP revenue was $426 million, an increase of 3% compared to the prior year.  Excluding the impact from currency, revenue for the division was flat to prior year, as a result of the general funding environment.
  • Genetic Systems division non-GAAP revenue was $256 million in the third quarter, an increase of 12 percent over the same period last year.  Excluding the impact from currency, revenue increased 8 percent.  Strong sales of the Ion Torrent PGM™ and related products, as well as, growth in forensic instrument placements were partially offset by lower sales of the 5500 instrument and consumables.
  • Regional revenue growth rates for the quarter compared to the same quarter of the prior year were as follows: the Americas grew 2 percent, Europe 5 percent, Asia Pacific 14 percent and Japan declined 2 percent.
  • Revenue from orders transacted through Life Technologies' eCommerce channels grew 8 percent during the quarter.  Over 50 percent of all transactions are processed using eCommerce platforms.

  • Product Highlights:

  • Continuing to build its consumables product portfolio, the company has launched several products that will be used in the research and applied markets.  These products include:
  • The launch of the first and only USDA approved Real-Time PCR test to detect Swine Influenza Virus with the VetMAX™-Gold SIV Detection Kit,
  • The MagMAX™ RNA and DNA Isolation Kits which help scientists to more efficiently and effectively isolate RNA and DNA from cancer tumor tissue samples,
  • Two diagnostic control products were also launched with the AcroMetrix® KRAS FFPE Process Controls and the AcroMetrix® Quantitative Panels, Plasma Controls and CSF Controls.  These research use only products monitor the performance of molecular tests across an entire workflow.
  • The company has signed an agreement with GlaxoSmithKline to develop a diagnostic to be used in companion with an innovative cancer therapy which is in phase III clinical trials. For more details, please reference press release dated October 25, 2011.
  • Extending its qPCR franchise, the company announced the QuantStudio™ 12k Flex Real-Time system.  This high throughput system can provide up to 110,000 data points in one workday.  The instrument can also run digital PCR.  For more details, please reference press release dated October 12, 2011.
  • Accelerating the pace of discovery by making research simpler, faster and more accurate, the company announced eight innovative Ion Torrent products including the launch of the Ion AmpliSeq™ Cancer Panel, the Ion Sequencing 200 Kit and the release of a 1 Gb dataset on the new Ion 318™ chip, demonstrating 100x scaling of the platform in under a year.  For more details, please reference press release dated October 12, 2011.

  • Fiscal Year 2011 OutlookSubject to the risk factors detailed in the Safe Harbor Statement section of this release, the company reiterated its expectations for fiscal year 2011 financial performance.   Revenue growth, excluding currency, is expected to be between 2 and 4 percent. This level of revenue growth is expected to result in approximately $3.70 to $3.80 of non-GAAP earnings per share.   The company will provide further detail on its business outlook during the webcast today.

    Webcast Details The company will discuss its financial and business results as well as its business outlook on its webcast at 4:30 PM ET today.  This webcast will contain forward-looking information.  The webcast will include a discussion of "non-GAAP financial measures" as that term is defined in Regulation G.  For actual results, the most directly comparable GAAP financial measures and information reconciling these non-GAAP financial measures to the company's financial results determined in accordance with GAAP, as well as other material financial and statistical information to be discussed on the webcast will be posted at the company's Investor Relations Web site at http://ir.lifetechnologies.com. The webcast can be accessed through the investor relations page of the Life Technologies' website at http://ir.lifetechnologies.com/events.cfm. A replay of the webcast will be available on the company's website through Tuesday, November 15, 2011.

    About Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

    Safe Harbor Statement Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and Life Technologies intend that such forward-looking statements be subject to the safe harbor created thereby.  Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of  the company. Such forward-looking statements include, but are not limited to, statements relating to financial projections, including revenue and pro forma EPS projections; success of acquired businesses, including cost and revenue synergies; development and increased flow of new products; leveraging technology and personnel; advanced opportunities and efficiencies; opportunities for growth; expectations of prospective new standards, new delivery platforms, and new selling specialization and effectiveness; and corporate strategy and performance.  A number of the matters discussed in this press release and presentation that are not historical or current facts deal with potential future circumstances and developments, including future research and development plans. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:  volatility of the financial markets; and the risks that are described from time to time in Life Technologies' reports filed with the SEC.  This press release and presentation speaks only as of its date, and the company disclaims any duty to update the information herein.

    Non-GAAP Measurements

    This press release includes certain financial information which constitutes "non-GAAP financial measures" as defined by the SEC.  The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most directly comparable GAAP measures, can be found at on the Investor Relations portion of the company's website at www.lifetechnologies.com.

    Investor and Financial Contacts:
    Agnes Lee
    Investor Relations
    (760) 603-7208

    LIFE TECHNOLOGIES CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONSAND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1)(in thousands, except per share data)

    For the three months
    ended September 30, 2011For the three months
    ended September 30, 2010(unaudited)GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRevenues$ 928,198

    $
    543

    (2)

    $  928,741$ 867,082

    $   1,568

    (2)

    $  868,650Cost of revenues

    315,062

    183

    (3)

    315,245282,505

    5,987

    (3)

    288,492Purchased intangibles amortization

    73,901

    (73,901)

    (4)

    -70,216

    (70,216)

    (4)

    -Gross profit

    539,235

    74,261613,496514,361

    65,797580,158Gross margin

    58.1%66.1%59.3%66.8%Operating expenses:Selling, general and administrative

    251,832

    (1,172)

    (5)

    250,660240,680

    (2,033)

    (5)

    238,647Research and development

    103,856

    (14,195)

    (5) (12)

    89,66190,057

    (756)

    (5)

    89,301Business consolidation costs

    23,126

    (23,126)

    (6)

    -17,714

    (17,714)

    (6)

    -Total operating expenses

    378,814

    (38,493)340,321348,451

    (20,503)327,948Operating income

    160,421

    112,754273,175165,910

    86,300252,210Operating margin

    17.3%29.4%19.1%29.0%Interest income

    919

    -9191,136

    -1,136Interest expense

    (37,992)

    6,572

    (7)

    (31,420)(35,206)

    8,474

    (7)

    (26,732)Other income (expense), net

    (3,039)

    -(3,039)(4,270)

    (405)

    (8)

    (4,675)Total other income (expense), net

    (40,112)

    6,572(33,540)(38,340)

    8,069(30,271)Income from operations beforeprovision for income taxes

    120,309

    119,326239,635127,570

    94,369221,939Income tax provision

    (24,335)

    (40,612)

    (9)

    (64,947)(22,327)

    (34,984)

    (9)

    (57,311)Net income

    95,974

    78,714174,688105,243

    59,385164,628Net loss attributable to non-controlling interests

    297

    (104)

    (10)

    193297

    (87)

    (10)

    210Net income attributable to controlling interest$   96,271$ 78,610$  174,881$ 105,540$ 59,298$  164,838Effective tax rate

    20.2%27.1%17.5%25.8%Add back interest expense for
    diluted earnings calculation,
    net of tax

    650

    (618)

    (11)

    3238

    -38Numerator for diluted earnings  per share$   96,921

    $ 77,992$  174,913$ 105,578

    $ 59,298$  164,876Earnings per common share:Basic earnings per share attributable to controlling interest

    $
    .54
    $
    .97
    $
    .57
    $
    .89
    Diluted earnings per share attributable to controlling interest

    $
    .52
    $
    .94
    $
    .56
    $
    .87
    Weighted average shares used in per share calculation:Basic179,859179,859184,196184,196Diluted186,812186,812190,149190,149(1)  The Company reports Non-GAAP results, which excludes business consolidation costs, amortization of purchase accounting adjustments to deferred revenue, fair market value adjustments to contingent consideration liabilities, charges for inventory revaluation, amortization of acquired intangibles and depreciation of acquired property, plant, and equipment to provide a supplemental comparison of the results of operations.  In addition, charges related to non-cash interest expense incurred as a result of the retrospective application of the bifurcation requirement between equity and debt prescribed by the Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic of Debt with Conversion and Other Options, charges associated with discontinued products, and the impact from the divestiture of our joint venture have been excluded from Non-GAAP results.   (2)  Adjust revenue related to credit usage on returns of a discontinued product of $0.1 million offset by the fair value amortization of purchased deferred revenue of $0.6 million for the three months ended September 30, 2011. Add back fair value amortization of purchased deferred revenue of $1.6 million for the three months ended September 30, 2010.   (3)  Adjust charges for a contingent consideration remeasurement of $0.2 million for the three months ended September 30, 2011 and add back noncash charges for purchase accounting inventory revaluations of $0.3 million and contingent consideration remeasurement gain of $6.3 million for the three months ended September 30, 2010.   (4)  Add back amortization of purchased intangibles.(5)  Add back depreciation of purchase accounting property, plant, and equipment revaluations.   (6)  Add back business consolidation costs.   (7)  Add back charges related to non-cash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $5.1 million and $8.5 million for the three months ended September 30, 2011 and 2010, respectively. Adjust for imputed finance charge of $1.5 million associated with contingent consideration on business acquisitions for the three months ended September 30, 2011.   (8)  Adjust for gain on impaired security recovery of $0.4 million for the three months ended September 30, 2010.   (9)  Non-GAAP tax differs from GAAP tax expense primarily because certain acquisition related costs such as restructuring, amortization of acquired intangibles, depreciation of acquired property, plant, and equipment, and fair market value adjustments to contingent consideration liabilities associated with certain acquisitions, and charges associated with discontinued products.  In addition, GAAP net income includes interest expense with related income tax benefits as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options but excluded for Non-GAAP purposes. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.(10)  Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant and equipment revaluations attributable to non-controlling interest, net of tax benefit.   (11)  Eliminate noncash interest charges from diluted earnings per share calculation, as the noncash interest is excluded from the calculation of Non-GAAP net income.   (12)  Add back contingent consideration fair value adjustment of $13.7 million for the three months ended September 30, 2011.   LIFE TECHNOLOGIES CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONSAND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1)(in thousands, except per share data)

    For the nine months
    ended September 30, 2011For the nine months
    ended September 30, 2010(unaudited)GAAPAdjustmentsNon-GAAPGAAPAdjustmentsNon-GAAPRevenues$ 2,765,227

    $
    5,111

    (2)

    $ 2,770,338$ 2,655,757

    $
    5,445

    (2)

    $ 2,661,202Cost of revenues

    955,840

    (539)

    (3)

    955,301857,259

    5,464

    (3)

    862,723Purchased intangibles amortization

    226,527

    (226,527)

    (4)

    -210,353

    (210,353)

    (4)

    -Gross profit

    1,582,860

    232,1771,815,0371,588,145

    210,3341,798,479Gross margin

    57.2%65.5%59.8%67.6%Operating expenses:Selling, general and administrative

    759,438

    (4,912)

    (5)

    754,526753,178

    (5,896)

    (5)

    747,282Research and development

    287,723

    (15,974)

    (5) (14)

    271,749266,754

    (2,088)

    (5)

    264,666Purchased in-process research and development

    -

    --1,650

    (1,650)

    (4)

    -Business consolidation costs

    56,468

    (56,468)

    (6)

    -66,426

    (66,426)

    (6)

    -Total operating expenses

    1,103,629

    (77,354)1,026,2751,088,008

    (76,060)1,011,948Operating income

    479,231

    309,531788,762500,137

    286,394786,531Operating margin

    17.3%28.5%18.8%29.6%Interest income

    2,960

    -2,9603,588

    -3,588Interest expense

    (123,911)

    24,130

    (7)

    (99,781)(116,033)

    30,965

    (7)

    (85,068)Loss on early retirement of debt

    -

    --(54,185)

    54,185

    (8)

    -Gain on divestiture of equity investments

    -

    --37,260

    (37,260)

    (9)

    -Other income (expense), net

    (7,980)

    -(7,980)(6,248)

    6,058

    (10)

    (190)Total other income (expense), net

    (128,931)

    24,130(104,801)(135,618)

    53,948(81,670)Income from operations beforeprovision for income taxes

    350,300

    333,661683,961364,519

    340,342704,861Income tax provision

    (65,534)

    (122,610)

    (11)

    (188,144)(57,229)

    (143,528)

    (11)

    (200,757)Net income

    284,766

    211,051495,817307,290

    196,814504,104Net loss attributable to non-controlling interests

    658

    (308)

    (12)

    350324

    (192)

    (12)

    132Net income attributable to controlling interest$
    285,424$ 210,743$
    496,167$
    307,614$ 196,622$
    504,236Effective tax rate

    18.7%27.5%15.7%28.5%Add back interest expense for
    diluted earnings calculation,
    net of tax

    716

    (618)

    (13)

    98139

    -139Numerator for diluted  earnings per share$
    286,140

    $ 210,125$
    496,265
    $
    307,753

    $ 196,622$
    504,375
    Earnings per common share:Basic earnings per share attributable to controlling interest

    $
    .59
    $
    2.76
    $
    .69
    $
    2.76
    Diluted earnings per share attributable to controlling interest

    $
    .54
    $
    2.67
    $
    .62
    $
    2.65
    Weighted average shares used in per share calculation:Basic179,751179,751182,516182,516Diluted185,946185,946190,356190,356(1)  The Company reports Non-GAAP results, which excludes business consolidation costs, amortization of purchase accounting adjustments to deferred revenue, fair market value adjustments to contingent consideration liabilities, charges for inventory revaluation, amortization of acquired intangibles and depreciation of acquired property, plant, and equipment to provide a supplemental comparison of the results of operations.  In addition, charges related to non-cash interest expense incurred as a result of the retrospective application of the bifurcation requirement between equity and debt prescribed by the Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic of Debt with Conversion and Other Options, costs associated with the early termination of outstanding indebtedness, charges associated with discontinued products and the impact from the divestiture of our joint venture have been excluded from Non-GAAP results.   (2)  Add back revenue related to returns of a discontinued product of $2.7 million and fair value amortization of purchased deferred revenue of $2.4 million for the nine months ended September 30, 2011. Add back fair value amortization of purchased deferred revenue of $5.4 million for the nine months ended September 30, 2010.   (3)  Add back charges for inventory reserves related to a discontinued product of $2.1 million and $0.5 million of purchase accounting related cost of revenue revaluation, offset by contingent consideration revaluation of $2.1 million for the nine months ended September 30, 2011.  Add back noncash charges for purchase accounting inventory revaluations of $0.8 million and adjust contingent consideration remeasurement gain of $6.3 million for the nine months ended September 30, 2010.   (4)  Add back amortization of purchased intangibles and write off of purchased in-process research and development.(5)  Add back depreciation of purchase accounting property, plant, and equipment revaluations.   (6)  Add back business consolidation costs.   (7)  Add back charges related to non-cash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $19.5 million and $31.0 million for the nine months ended September 30, 2011 and 2010, respectively. Adjust for imputed finance charge of $4.6 million associated with contingent consideration on business acquisitions for the nine months ended September 30, 2011.   (8)  Add back loss on early retirement of debt.   (9)  Adjust for gain on divestiture of equity investments.   (10)  Adjust for gain on impaired security recovery of $7.1 million and gain on foreign currency related to joint venture divestiture of $1.0 million offset by loss on discontinuance of cash flow hedge of $12.9 million and joint venture purchase accounting adjustment of $1.2 million for the nine months ended September 30, 2010.(11)  Non-GAAP tax differs from GAAP tax expense primarily because certain acquisition related costs such as restructuring, amortization of acquired intangibles, depreciation of acquired property, plant, and equipment, and fair market value adjustments to contingent consideration liabilities associated with certain acquisitions and charges associated with discontinued products.  In addition, GAAP net income includes interest expense with related income tax benefits as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options but excluded for Non-GAAP purposes. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.(12)  Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant and equipment revaluations attributable to non-controlling interest, net of tax benefit.   (13)  Eliminate noncash interest charges from diluted earnings per share calculation, as the noncash interest is excluded from the calculation of Non-GAAP net income.   (14)  Add back contingent consideration fair value adjustment of $13.7 million for the nine months ended September 30, 2011.   LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30, December 31, (in thousands)

    20112010ASSETS (unaudited) Current assets:Cash and short-term investments

    $
    35,938$
    854,801Trade accounts receivable, net of allowance for doubtful accounts

    634,372587,456Inventories

    393,775323,318Prepaid expenses and other current assets

    189,017280,950Total current assets

    1,853,1022,046,525Long-term assets

    7,193,3917,439,674Total assets

    $
    9,046,493
    $
    9,486,199
    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Current portion of long-term debt

    $
    445,732$
    347,749Accounts payable, accrued expenses and other current liabilities

    $
    958,712798,636Total current liabilities

    1,404,4441,146,385Long-term debt

    2,298,0722,727,624Other long-term liabilities

    767,5791,174,161Stockholders' equity

    4,576,3984,438,029Total liabilities and stockholders' equity

    $
    9,046,493
    $
    9,486,199
    LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFor the nine monthsended September 30,(in thousands)(unaudited)

    20112010Net income$  284,766$ 307,290Add back amortization and share-based compensation

    289,912281,228Add back depreciation

    90,98891,965Balance sheet changes

    (153,355)(113,929)Other noncash adjustments

    (19,104)(52,036)Net cash provided by operating activities

    493,207514,518Capital expenditures

    (65,779)(83,215)Free cash flow427,428431,303Net cash provided by (used in) investing activities

    (48,645)244,597Net cash used in financing activities

    (601,228)(774,688)Effect of exchange rate changes on cash

    3,0925,103Net increase (decrease) in cash and cash equivalents$ (219,353)$ (93,685)
    '/>"/>

    SOURCE Life Technologies
    Copyright©2010 PR Newswire.
    All rights reserved


    Related biology technology :

    1. Reprints Desk and Deep Web Technologies Announce Agreement to Integrate Research Services
    2. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
    3. Omega Protein Announces Retention of Lipid Technologies, LLC
    4. Palatin Technologies to Present at 10th Annual BIO Investor Forum
    5. BioStorage Technologies to Host Global Sample Management Benchmarking Symposium at International Contract Services Expo
    6. Microring device could aid in future optical technologies
    7. Life Technologies Announces Flagship PCR Instrument that Enables Cost-Effective, High-Throughput Screening Applications
    8. Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing
    9. BioStorage Technologies Expands Liquid Nitrogen Storage in Germany-based Biorepository Facility
    10. Life Technologies Sets 3rd Quarter 2011 Earnings Release Date for Tuesday, October 25, 2011
    11. Lifeline Biotechnologies and Depository Trust Company
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
    (Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
    (Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
    (Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
    Breaking Biology Technology:
    (Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
    (Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
    (Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
    Breaking Biology News(10 mins):